APM Stock Overview
Through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Aptorum Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.45 |
| 52 Week High | US$17.49 |
| 52 Week Low | US$1.35 |
| Beta | 1.27 |
| 11 Month Change | -12.99% |
| 3 Month Change | -50.07% |
| 1 Year Change | -9.19% |
| 33 Year Change | -94.02% |
| 5 Year Change | -99.08% |
| Change since IPO | -98.99% |
Recent News & Updates
Recent updates
Aptorum Group GAAP EPS of -$0.05
Oct 03Is Aptorum Group (NASDAQ:APM) In A Good Position To Deliver On Growth Plans?
Jul 14
Aptorum Group: Advancing Oncology, Autoimmune & Infectious Disease Therapies
Feb 11Aptorum inks development agreement with Exeltis
May 06We Think Shareholders Should Be Aware Of Some Factors Beyond Aptorum Group's (NASDAQ:APM) Profit
Apr 26Do Institutions Own Aptorum Group Limited (NASDAQ:APM) Shares?
Jan 16Aptorum files for early-stage trial for ALS-4 in Canada
Dec 21Shareholder Returns
| APM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.8% | -0.7% | -1.6% |
| 1Y | -9.2% | 19.8% | 30.8% |
Return vs Industry: APM underperformed the US Biotechs industry which returned 19.8% over the past year.
Return vs Market: APM underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| APM volatility | |
|---|---|
| APM Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: APM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: APM's weekly volatility has decreased from 81% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 3 | Ian Huen | www.aptorumgroup.com |
Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections.
Aptorum Group Limited Fundamentals Summary
| APM fundamental statistics | |
|---|---|
| Market cap | US$7.95m |
| Earnings (TTM) | -US$2.82m |
| Revenue (TTM) | US$431.38k |
18.4x
P/S Ratio-2.8x
P/E RatioIs APM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APM income statement (TTM) | |
|---|---|
| Revenue | US$431.38k |
| Cost of Revenue | US$420.81k |
| Gross Profit | US$10.57k |
| Other Expenses | US$2.84m |
| Earnings | -US$2.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 2.45% |
| Net Profit Margin | -654.80% |
| Debt/Equity Ratio | 0% |
How did APM perform over the long term?
See historical performance and comparison